Clonal Mesenchymal Stem Cell Lines for Consistent Exosome Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies face challenges such as tumor formation, limited therapeutic efficacy, and heterogeneity in mesenchymal stromal cells (MSCs), making it difficult to produce a consistent and effective fraction of MSC-derived exosomes for clinical applications, particularly in treating conditions like perinatal brain injury.
Innovation Solution
A method is developed to produce a clonal mesenchymal stem cell line from human induced pluripotent stem cells (hiPSCs), which are immortalized and characterized for their exosome production potential, ensuring a standardized, reproducible, and therapeutically active MSC-derived extracellular vesicle production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adult stem cells are used for therapy, then tissue regeneration and homeostasis maintenance are improved, but heterogeneity and limited therapeutic efficacy occur
Solution Approach 1:
The patent segments the heterogeneous adult stem cell population into clonal lines derived from single cells. By isolating and cultivating individual stem cells to form clonal populations, the invention eliminates heterogeneity while maintaining therapeutic efficacy. Each clonal line represents a uniform cell population with consistent properties, solving the contradiction between therapeutic effectiveness and cellular homogeneity.
Solution Approach 2:
The patent changes the fundamental parameter of cell origin from heterogeneous adult stem cells to homogeneous clonal lines. Through selective cultivation and cloning, the invention transforms the cell population parameter from diverse to uniform, enabling consistent therapeutic outcomes while eliminating the heterogeneity problem inherent in adult stem cell therapies.
2Reliability
If stem cells are injected for therapy, then tissue regeneration is stimulated, but tumor formation and cerebral infarction risks increase
Solution Approach 1:
The patent extracts the therapeutic function from the entire stem cell population and focuses it on specific clonal lines that have been selected and characterized for their therapeutic properties. By isolating and using only the beneficial clonal populations, the invention maintains therapeutic efficacy while eliminating the harmful effects associated with heterogeneous adult stem cell populations, such as tumor formation and infarction risks.
Solution Approach 2:
The patent creates copies of successful clonal lines that have demonstrated therapeutic efficacy. By replicating and expanding proven clonal populations, the invention ensures consistent therapeutic results while avoiding the risks associated with using diverse adult stem cell populations. The clonal copies maintain uniform therapeutic properties without the harmful variability present in original adult stem cells.
3Reliability
If MSCs are used to treat perinatal brain injury, then neuroprotective effects are observed, but batch variability and immune reactions occur
Solution Approach 1:
The patent segments the MSC population into defined clonal lines, each with consistent neuroprotective properties. By using clonal lines rather than heterogeneous MSC populations, the invention eliminates batch variability while maintaining reliable neuroprotective effects. Each clonal line provides uniform therapeutic output, ensuring consistent treatment results across different batches.
Solution Approach 2:
The patent changes the composition parameter of MSC preparations from heterogeneous to homogeneous clonal lines. This parameter change eliminates batch variability and ensures consistent neuroprotective effects. The standardized clonal lines provide reproducible therapeutic outcomes, solving the contradiction between therapeutic reliability and batch consistency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a consistent and effective supply of MSC-derived exosomes with immunomodulatory activities, enhancing their therapeutic potential for conditions like perinatal brain injury and other diseases, while minimizing immune reactions and batch variability.
Implementation Method 1
generating therefrom an immortalized clonal cell line of mesenchymal stem cells
Implementation Method 2
Exosomes derived from specific intracellular parts called multivesicular bodies (MVBs) and released and secreted to the outside of cells
Implementation Method 3
when fusion between multivesicular bodies and plasma membranes occurs, vesicles are released to the outside of cells
Data Source
AI summary
The invention relates to mesenchymal stem cell derived exosomes produced by a method comprising the steps of,performing a method of producing a clonal mesenchymal stem cell line capable of producing exosomes (MSC-derived extracellular vesicles) comprising the steps of, providing human induced pluripotent stem cells (hiPSCs),generating therefrom an immortalized clonal cell line of mesenchymal stem cells (IMSCs),characterizing the potential of the IMSCs to produce exosomes,cultivating the desired IMSCs such that the IMSCs produce exosomes,isolating the exosomes.